Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The multi-year collaboration will combine Tempus’ sequencing capabilities and industry-leading platform of integrated clinical...
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today the appointment of Lauren Silvis as its Senior Vice President of External Affairs. Silvis will oversee regulatory, public policy and government affairs, operating from Tempus’ office to...
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today that it is providing its de-identified datasets via a data subscription, enabling researchers to leverage unique, longitudinally-updated clinical and molecular data at scale, which will help accelerate...
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announces the appointment of Joel Dudley, PhD, as its Senior Vice President of Research. In his role, Dr. Dudley is responsible for leading Tempus’s research and development efforts...
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission...
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today a new service, Tempus Integrated Molecular Evaluation (TIME) Trial, which aims to increase clinical trial enrollment and participation for cancer patients who are treated in both the...
Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M financing at a value of $3.1 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and funds and accounts managed by...
Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced a new research collaboration with the Feist-Weiller Cancer Center at LSU aimed at improving outcomes for patients battling brain cancer. As part of this research study, Tempus will work...
Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data announced a new collaboration with the Huntsman Cancer Institute at the University of Utah (HCI) aimed at improving outcomes for patients diagnosed with pancreatic cancer. While personalized treatment approaches have...
The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aims to describe the performance (both safety and efficacy...